Reactivation of hepatatis B in a patient with breast cancer treated using capecitabine.

Marco Fiore


Reactivation of HBV is a well-recognized complication following immunosuppressive drug therapy in patients with past infection. The International Guidelines for HBV screening before cytotoxic or immunosuppressive therapy are controversial.

The literature data does not report HBV reactivation due to capecitabine so the international guidelines no recommend prophylaxis in such situation.

In this paper, we describe the history of HBV reactivation of hepatatis B in a female patient with breast cancer treated using capecitabine observed in a Unit of Infectious Diseases of north-est of Italy.

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.